ADC announces data presentation from LOTIS-7 Phase 1b clinical trial

ADC Therapeutics (ADCT) announced data presentations from the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA, or loncastuximab tesirine-lpyl, in combination with glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma, or DLBCL. Updated results will be shared at the European Hematology Association 2025 Congress taking place in Milan, Italy with an oral encore presentation at the 18th International Conference on Malignant Lymphoma, or ICML, in Lugano, Switzerland. Updated LOTIS-5 safety run-in data evaluating the combination of ZYNLONTA plus rituximab, or Lonca-R, will also be featured at EHA2025. The LOTIS-7 abstract provides data as of the January 17 cutoff, in which 31 patients received greater than or equal to1 ZYNLONTA dose and were safety evaluable, with 22 patients efficacy evaluable. Four of these patients converted to complete response within 3 weeks after the data cutoff and are included as CRs. Updated data will be presented during EHA2025. Key highlights in the LOTIS-7 abstract are as follows: In the efficacy evaluable population, overall response rate, or ORR, was 95.5%, complete response, or CR, rate was 90.9%, and median duration of response, or DOR, was not reached. Among 31 patients treated, the combination demonstrated a manageable safety profile. Adverse events were consistent with known profiles of the individual agents, with neutropenia being the most common Grade greater than or equal to3 treatment-emergent adverse event. Grades 3/4 TEAEs of interest included generalized edema, pericardial effusion, photosensitivity reaction, rash, sepsis and pneumonia. Grade 1/2 AE of CRS and ICANS were observed with no Grade greater than or equal to at the time of data cut off.